Loading
A phase 3 trial of Daraxonrasib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) is a phase 3 interventional study registered as NCT06881784 by Revolution Medicines, Inc., with 590 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-12-01. Interventions recorded: daraxonrasib, docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma). No results are recorded here; the registry entry is the source.
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares Revolution Medicines, KRAS & RAS inhibitors, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares KRAS & RAS inhibitors, Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Revolution Medicines, Daraxonrasib, KRAS & RAS inhibitors, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.